// App-Quantinova.ai

4093 : Association of disease progression, health-related quality of life (HRQoL), and utility in patients (pts) with advanced, nonfunctional, well-differentiated gastrointestinal (GI) or lung neuroendocrine tumors (NET) in the phase 3 RADIANT-4 trial.

Researchers

Presenter

  • Simron Singh

Principal Investigators

  • Marianne E. Pavel

  • Jonathan R. Strosberg

  • Lida Bubuteishvili-Pacaud

  • Evgeny Degtyarev

  • Maureen Neary

  • Matthias Hunger

  • Jennifer Eriksson

  • Nicola Fazio

  • Matthew H. Kulke

  • James C. Yao

Medical Centers

  • Odette Cancer Center, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

  • Charite Berlin Campus Virchow-Klinikum, Berlin, Germany

  • Moffitt Cancer Center, Tampa, FL

  • Novartis AG, Basel, Switzerland

  • Novartis AG, Basel, Switzerland

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Mapi Group, Munchen, Germany

  • Mapi Group, Stockholm, Sweden

  • Istituto Europeo di Oncologia, Milano, Italy

  • Dana-Farber Cancer Institute, Boston, MA

  • GI Medical Oncology Department, The University of Texas MD Anderson Cancer Center, Houston, TX

Locations

  • Canada

  • Italy

  • Germany

  • Switzerland

  • United States

  • Sweden

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Neuroendocrine tumors

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved